Risk factors of eclampsia other than hypertension: pregnancy-induced antithrombin deficiency and extraordinary weight gain

Takashi Yamada¹*, MD, PhD: Corresponding author and data analysis
Tomoyuki Kuwata², MD, PhD: Data sampling
Hideo Matsuda³, MD, PhD: Data sampling
Keizo Deguchi⁴, MD: Data sampling
Mamoru Morikawa¹, MD, PhD: Data analysis
Takahiro Yamada¹, MD, PhD: Data sampling
Kennichi Furuya³, MD, PhD: Adviser
Shigeki Matsubara², MD, PhD: Adviser
Hisanori Minakami¹, MD, PhD: Director and institutional reviewer

*Corresponding author

¹Department of Obstetrics, Hokkaido University Graduate School of Medicine, Kita-ku N14 W6, Sapporo 060-8638, Japan
²Department of Obstetrics and Gynecology, Jichi Medical University School of Medicine, Tochigi, Japan
³National Defense Medical College, Saitama, Japan
⁴Sapporo Toho Hospital, Sapporo, Japan
Abstract

OBJECTIVE: Recent findings suggest that cerebral edema is a characteristic finding on magnetic resonance imaging (MRI) in women with eclampsia and that pregnancy-induced antithrombin deficiency (PIATD) may reflect enhanced vascular permeability and may allow the retention of excess water in the interstitial space. Whether PIATD and extraordinary weight gain (EOWG) are risk factors for eclampsia remains to be studied.

METHODS: The medical records of 11 women with eclampsia among 17,522 deliveries were reviewed retrospectively with respect to changes in the laboratory data and the maternal body weight. PIATD was defined as a perinatal antithrombin activity ≤ 65% of the normal activity levels with an antenatal decline and/or a prompt postnatal increase. A large net weight gain during the last two antenatal weeks > 97.5th percentile value (> 4.01kg) obtained from 272 control women with neither hypertension nor PIATD was defined as EOWG. Relative risk (RR) was obtained on the assumption that the prevalences of PIATD and EOWG were 2.0% and 2.5%, respectively, among 17,511 women who did not develop eclampsia.

RESULTS: The duration of hypertension until an eclamptic fit was within 7 days in all 11 cases. PIATD and EOWG were observed in 6 (54.5%) and 2 (18.2%) cases, yielding an RR (95% confidential interval) of 57.9 (17.7 – 188.7) and 8.65 (1.87 – 39.91) for eclampsia among women with PIATD and EOWG, respectively.

CONCLUSIONS: PIATD and EOWG may be risk factors for eclampsia.

(Key words: eclampsia, edema, pregnancy-induced antithrombin deficiency)
Introduction

Current criteria for pregnancy-induced hypertension define pregnancy-induced hypertension as hypertension with or without proteinuria occurring at or after 20 weeks of gestation but resolving by 12 weeks postpartum [18]. Based on these criteria, women with edema and/or proteinuria alone are not diagnosed as having pregnancy-induced hypertension until they exhibit additional hypertension. However, absolute blood pressure alone is not always a dependable indicator of the severity of preeclampsia, because some women with proteinuria alone develop life-threatening eclampsia [2, 5, 7, 11]. Approximately 20% to 50% of women do not have hypertension at their last antenatal visit within a week before their first convulsive fit [2, 7, 11]. Similarly, a case of a woman who exhibited edema alone but who eventually progressed to a serious clinical condition has been documented [8]. Therefore, new clinical or laboratory parameters other than hypertension are needed to predict and prevent the occurrence of eclampsia.

Some women develop a gradual decline in antithrombin (AT) activity during the late stage of pregnancy, even in the absence of hypertension [12, 13, 25]. This decline in AT activity continues until the day of or one day after delivery, and a prompt normalization of AT activity occurs postpartum in such patients with pregnancy-induced AT deficiency (PIATD) [13]. The incidence of PIATD, defined as a gradual decline in antithrombin activity to ≤ 65% of the normal activity levels, is approximately 20% among women with PIH [17] and approximately 1.0% among women with otherwise healthy singleton pregnancies [17, 26], and women with PIATD are likely to develop perinatal liver dysfunction [13]. Liver dysfunction with transient thrombocytopenia and a transient elevation in serum LDH, namely HELLP syndrome, is considered to be a severe
condition irrespective of the degree of hypertension [18]. Patients with edema and/or PIATD may be at an increased risk of developing eclampsia irrespective of the degree of hypertension based on the following reasons: (i) edema can result from enhanced vascular permeability [6]; (ii) cerebral edema is a characteristic finding on magnetic resonance imaging (MRI) in patients with eclampsia [4, 10, 23]; (iii) vascular permeability is thought to be enhanced in patients with PIATD [8, 17]; (iv) a lower antithrombin activity possibly reflects an enhanced vascular permeability [8, 16, 17]; and (v) patients with either PIATD or eclampsia are likely to develop HELLP syndrome [13, 20]. Accordingly, we conducted this retrospective study to determine whether women with eclampsia are likely to exhibit PIATD and/or abnormal weight gain prior to an eclamptic fit.

**Methods**

This study was conducted retrospectively after approval by the institutional review board at Hokkaido University Hospital. Patients with a diagnosis of eclampsia were selected from amongst 17,522 women who had received antenatal care and given birth during the 67-month period between January 2005 and September 2010 at four hospitals: Sapporo Toho Hospital, Jichi Medical School Hospital, National Defense Medical College Hospital, and Hokkaido University Hospital. The medical records of these women with eclampsia were reviewed retrospectively with respect to changes in laboratory data and maternal body weight during pregnancy and postpartum. Patients who were referred to those hospitals after an eclamptic fit were excluded from the present analyses.

Women who developed hypertension (systolic blood pressure ≥ 140 mmHg or
diastolic blood pressure $\geq 90$ mmHg) alone, proteinuria ($\geq 0.3$g/day) alone, or both hypertension and proteinuria at $\geq 20$ weeks of gestation were diagnosed as having gestational hypertension, gestational proteinuria, and preeclampsia, respectively. A positive spot urine test result ($\geq 2+$) or a protein concentration in the urine of $\geq 25$ mg/dL was considered to indicate significant proteinuria ($\geq 0.3$ g/day).

Pregnancy-induced antithrombin deficiency (PIATD) was defined as a gradual decline in antithrombin (AT) activity to $\leq 65\%$ of the normal activity levels or a perinatal AT activity level of $\leq 65\%$, with a prompt increase after delivery.

Data on antenatal AT activity were not available in the majority of 17,522 women. Therefore, maternal body weight was examined prospectively at two weeks prior to delivery, on the day of delivery, and one and four weeks postpartum in 272 women who developed neither hypertension nor PIATD and consecutively gave birth to a singleton term infant (age and gestational week at delivery, 30.8±5.2 years old and 38.1±1.8, respectively) at Hokkaido University Hospital between January 1, 2009 and June 30, 2010 to determine the normal changes in maternal body weight among women with neither hypertension nor PIATD. Pre-pregnancy body weight, weight gain during pregnancy, and body weight at delivery were 53.8 ± 11.0 kg, 9.7 ± 4.0 kg, and 63.5 ± 4.0 kg, respectively. Cesarean delivery rate was 40.1% in these 272 women. The net changes in body weight from the day of delivery were calculated in these 272 women. Women who exhibited a larger (> 97.5th percentile) net change in body weight during the last two antenatal weeks were judged as having extraordinary weight gain (EOWG).

PIATD occurs in approximately 20% of women with pregnancy-induced hypertension [17] and in approximately 1.0% of women with otherwise healthy singleton pregnancies [17, 26]. Since pregnancy-induced hypertension occurs in
approximately 5.0% of women with singleton pregnancies, PIATD occurs in approximately 2.0% of general pregnant women with singleton pregnancies. Since information on the antenatal weight gain and perinatal AT activity were not available in the majority of the 17,511 women who did not develop eclampsia in this study, we assumed that the prevalence of PIATD would be 2.0% among these 17,511 women and that the 97.5th percentile value for the net weight gain during the last two antenatal weeks obtained from 272 control women would be applicable to these 17,511 women. Then, the relative risk (RR) and 95% confidence interval (95%CI) for developing eclampsia was calculated among women with PIATD or EOWG.

Statistical analyses were performed using the JMP8 statistical software package (SAS, Cary, NC). Differences in the means were tested using the Tukey-Kramer HSD (honestly significant difference) test between each group, and categorical variables were compared using the Fisher exact test. A P value of less than 0.05 was considered to indicate statistical significance.

Results

Among the 17,522 women who gave birth at four hospitals during the study period, 11 women developed eclampsia (Table 1), resulting in an incidence of 1 in 1,593 women. Nulliparous women accounted for 72.7% (8/11) of the cases. The antenatal diagnosis was preeclampsia in 6 cases and gestational hypertension in 4 cases. However, hypertension was first observed on the day of the eclamptic fit in five cases (Cases 5, 8-11), one day prior to the fit in two cases (Cases 3 and 6), and three, four and six days prior to the fit in one case each (Cases 7, 2 and 1, respectively). Hypertension was not recognized until the eclamptic fit in one case (Case 4). Thus, the time interval after the
diagnosis of hypertension until the eclamptic fit was within 7 days in all the cases.

PIATD was observed in 6 (54.5%) of the 11 cases (Table 1). An antenatal decline in the AT activity was observed in three cases (Cases 1, 2, and 3) (Fig. 1). Although the antenatal AT activity was not available in the other three women with PIATD (Cases 4, 6, and 8), a prompt postnatal increase in AT activity was observed. In the other five women without PIATD, the lowest AT activity was 72%, 77%, and 82% on the day of delivery for Cases 5, 7, and 9, respectively, 89% on postpartum day 4 for Case 10, and 89% at one day prior to delivery for Case 11.

In the control group, comprised of 272 women with neither PIATD nor hypertension, the antenatal weight gain (median) during the last two weeks was 0.76 kg [2.5th – 97.5th percentile value: -1.66 kg – 4.01 kg], and the postnatal weight loss was 4.70 kg [0.40 kg – 9.20 kg] and 7.55 kg [3.05 kg – 12.82 kg] on postpartum days 7 and 28, respectively [shadow area in Fig. 2]. Six women with EOWG (> 97.5th percentile weight gain during the last two antenatal weeks, > 4.01 kg) exhibited a weight gain of 6.2 ± 2.2 kg (mean ± SD) during the last two antenatal weeks and a significantly larger weight loss of 11.1 ± 5.1 kg during the 4 weeks postpartum, compared with the other women with a smaller antenatal weight gain (Table 2). Two (18.2%) of the 11 cases (Cases 1 and 2) exhibited a larger antenatal weight gain during the last two antenatal weeks (Fig. 2) exceeding the 97.5th percentile value (> 4.01kg) of the control women and were judged to have EOWG.

The number of women with PIATD would be 350 (2.0% of 17,511) among 17,511 women without eclampsia, based on the assumption described in the Methods section, and 6 among the 11 cases in this study. Thus, the frequency of eclampsia would be 1.7% (6/356) for women with PIATD and 0.029% (5/17,166) for women without PIATD,
yielding an RR (95%CI) of 57.9 (17.7 – 188.7) for the development of eclampsia among women with PIATD, compared with women without PIATD. The number of women with EOWG (antenatal weight gain during the last two antenatal weeks > 4.01kg) would be 437 (2.5% of 17,511) among the 17,511 women without eclampsia, based on the assumption described in the Methods section, and 2 among the 11 cases in this study. Thus, the frequency of eclampsia would be 0.46% (2/439) for women with EOWG and 0.053% (9/17,083) for women without EOWG, yielding an RR (95%CI) of 8.65 (1.87 – 39.91) for the development of eclampsia among women with EOWG, compared with women without EOWG.

Discussion

PIATD was observed in 54.5% (6/11) of the women with eclampsia in this study. Since PIATD occurs less frequently among women without eclampsia, i.e., in approximately 20% of women with pregnancy-induced hypertension [17] and in approximately 1.0% of women with otherwise healthy singleton pregnancies [17, 26], this study suggests that women with PIATD are likely to experience an eclamptic fit, supporting our hypothesis. If we assumed that the general incidence of PIATD would be 2.0%, women with PIATD would have a 58-fold higher risk (95%CI, 17.7 – 188.7) of developing eclampsia, compared with women without PIATD, suggesting that PIATD is a risk factor for eclampsia.

EOWG defined as an antenatal weight gain during the last two antenatal weeks > 4.01kg was observed in two of the 11 cases in the present study, suggesting that women with EOWG are likely to experience an eclamptic fit. If we assume that the 97.5th percentile value of the net weight gain (> 4.01kg) during the last two antenatal weeks
obtained from 272 control women would be applicable to general pregnant women without eclampsia, women with EOWG had an 8.7-fold higher risk (95% CI, 1.87 – 39.91) of developing eclampsia, compared with women without EOWG, in this study. In addition, women with a larger weight gain of > 97.5th percentile value during the last two antenatal weeks exhibited a significantly larger weight loss during the first four postnatal weeks than the other women (Table 2, Fig. 2). Since excessive weight gain during the last two antenatal weeks and postnatal excessive weight loss indicate edema arising from the accumulation of excess water in the interstitial space, this study suggests that marked edema during the final stage of pregnancy is a risk factor for eclampsia.

PIATD, marked edema, and eclampsia may be related to each other pathogenetically. An increase in water retention is a normal physiological alteration during pregnancy. Clearly demonstrable pitting edema of the ankles and legs is seen in most pregnant women, especially during the late stages of pregnancy [1]. Edema resulting from the retention of excess water in the interstitial space can be massive in women with pregnancy-induced hypertension, mainly because of the increased blood vessel permeability [3, 19], and usually results in hemoconcentration and a decrease in the circulating plasma volume in patients with pregnancy-induced hypertension [21, 22]. The process involved in the retention of water is reversed by parturition, and excess water in the interstitial space returns into the intravascular space, resulting in a fall in the hematocrit value and the excretion of the excess water in the urine. This enables the edema to resolve. The extent of the postpartum decrease in the hematocrit value may therefore reflect the degree of antenatal hemoconcentration and the decrease in the circulating plasma volume. Women with PIATD show a large postnatal decrease in the
hematocrit value, irrespective of the presence or absence of hypertension, suggesting the antenatal presence of increased blood vessel permeability and hemoconcentration in women with PIATD [17]. On the other hand, a considerable amount of antithrombin is detected in the ascites of pregnant women with generalized edema, suggesting that antithrombin escapes from the blood into the interstitial space in the presence of the increased blood vessel permeability [16]. This phenomenon partially explains the gradual decline in antithrombin activity in women with PIATD. In addition, since enhanced coagulation-fibrinolysis is notable characteristics in women with PIATD showing perinatal increase in D-dimer and perinatal decrease in fibrinogen [15], enhanced coagulation-fibrinolysis also contributes to PIATD. Thus, PIATD and edema are related to each other through a common background of increased blood vessel permeability, and antithrombin activity may reflect the degree of vascular permeability. Indeed, two of the six women with PIATD exhibited EOWG in this study. The posterior reversible encephalopathy syndrome seen on MRI findings obtained in Cases 1 and 2 is a characteristic finding frequently seen in patients with eclampsia [10, 23] and represents subcortical edema without infarction [4]. Although the precise mechanisms involved in the formation of subcortical edema are unknown, the increased blood vessel permeability may contribute to the formation of subcortical edema, similar to the mechanisms involved in generalized edema and PIATD.

Proteinuria developed in 6 patients with eclampsia at the same time point when hypertension developed in the present study. Some patients with isolated proteinuria subsequently develop hypertension [14, 15] and proteinuria alone may also be associated with the decrease in AT activity; in comparison with 19 women diagnosed as having proteinuria preceding preeclampsia and 18 women diagnosed as having
gestational proteinuria at 12 weeks postpartum, significant differences are observed in AT activity (77.4±13.0% vs. 89.7±8.4%, respectively) and the rate of AT activity < 70% (42.1% vs. 22.2%, respectively) [15]. Since AT activity is 106±12% at 36.8±1.2 weeks of gestation in 663 women with singleton pregnancies in the absence of preeclampsia and the rate of AT activity < 80% is less than 5.0% [25], AT activity of 89.7±8.4% and the rate of AT activity < 70% (22.2%) in the 18 women with gestational proteinuria [15] appear to be lower and higher than corresponding figures, respectively in women without proteinuria.

The present study included only women who had received antenatal care and given birth at four secondary or tertiary hospitals (one secondary hospital and three university hospitals). This may explain why there were no women with eclamptic fit before 36 weeks of gestation in the present study because these hospitals generally provide more intensive cares for complicated women than general obstetrical institutions. Although not verified, it is possible that women who develop eclamptic fit at preterm exhibit hypertension for longer time compared with women who develop eclamptic fit at term. As previously mentioned, the duration of hypertension until the eclamptic fit was relatively short; the time interval after the diagnosis of hypertension until the eclamptic fit was within 7 days in all 11 cases in this study. In studies performed in the United Kingdom, hypertension was absent in 68 of 325 (21%) women with eclampsia in 1992 [2] and in 113 of 214 (53%) women with eclampsia between February 2005 and February 2006 at the time of their last antenatal visit and within 1 week of their first convulsion [7]. In a study performed in Japan in 2004, pregnancy-induced hypertension was not diagnosed before the eclamptic fit in 30 of the 54 (56%) women with eclampsia [11]. In Sweden, during 1991–1992, the incidence rate of eclampsia (3.3/10,000
pregnancies) increased significantly compared with the incidence (1.5/10,000 pregnancies) in 1976–1980 [9], raising the question of whether the incidence of eclampsia can be reduced by the earlier diagnosis and treatment of preeclampsia. As already described, the diagnosis of pregnancy-induced hypertension is not made in approximately 50% of women who develop eclampsia. This suggests the need for physical and/or laboratory parameters other than hypertension to predict the development of and thereby prevent the occurrence of eclampsia. The monitoring of weight gain during the late stage of pregnancy and the measurement of antithrombin activity in women with excessive weight gain may be helpful for detecting women with a high risk of eclampsia.

Extraordinary weight gain defined as an antenatal weight gain during the last two antenatal weeks > 4.01kg necessarily reflected excessive water retention and was assessed easily and objectively in the present study. Despite the elimination of edema as a diagnostic criteria for preeclampsia in many countries and the fact that edema can occur in normal pregnancy [24], the present study suggested that excessive water retention was a physical risk factor for eclampsia. The close attention to weight gain at term may be helpful for the detection of women at high risk of developing eclampsia. Since antithrombin escapes from the blood into the interstitial space in the presence of increased blood vessel permeability [14, 15], antithrombin activity may reflect the degree of blood vessel permeability. The present study suggested that pregnancy-induced antithrombin deficiency was a laboratory risk factor for eclampsia. However, this study dealt with only a small number of women with eclampsia. A larger and well-controlled study is clearly needed to confirm our results.
References


Figure Legends

Figure 1: Perinatal changes in antithrombin activity in 6 women who developed eclampsia and pregnancy-induced antithrombin deficiency.

Figure 2: Perinatal changes in maternal body weight in two women who developed eclampsia and extraordinary weight gain. The shaded area indicates the range of the 2.5th – 97.5th percentile value obtained from 272 control women with neither hypertension nor pregnancy-induced antithrombin deficiency. The dotted line in the center of the shaded area indicates the median value.
Table 1. Clinical characteristics of 11 women with eclampsia

<table>
<thead>
<tr>
<th>Case number</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>36</td>
<td>35</td>
<td>24</td>
<td>36</td>
<td>38</td>
<td>38</td>
<td>31</td>
<td>21</td>
<td>19</td>
<td>36</td>
<td>38</td>
</tr>
<tr>
<td>Parity</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Pre-pregnancy Body weight (kg)</td>
<td>54.0</td>
<td>48.0</td>
<td>78.0</td>
<td>54.6</td>
<td>55.0</td>
<td>61.0</td>
<td>56.8</td>
<td>51.0</td>
<td>52.9</td>
<td>56.0</td>
<td>49.0</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.7</td>
<td>18.5</td>
<td>27.3</td>
<td>22.8</td>
<td>21.8</td>
<td>24.4</td>
<td>24.0</td>
<td>21.2</td>
<td>24.8</td>
<td>21.3</td>
<td>21.5</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>67.3</td>
<td>73.0</td>
<td>89.6</td>
<td>65.0</td>
<td>64.1</td>
<td>74.2</td>
<td>63.7</td>
<td>66.7</td>
<td>58.9</td>
<td>65.5</td>
<td>58.4</td>
</tr>
<tr>
<td>Time of onset Hypertension*</td>
<td>36–4/7</td>
<td>40–5/7</td>
<td>36–2/7</td>
<td>no</td>
<td>38–3/7</td>
<td>40–1/7</td>
<td>41–0/7</td>
<td>39–4/7</td>
<td>38–1/7</td>
<td>40–5/7</td>
<td>40–4/7</td>
</tr>
<tr>
<td>Proteinuria*</td>
<td>36–4/7</td>
<td>40–5/7</td>
<td>36–2/7</td>
<td>no</td>
<td>38–3/7</td>
<td>no</td>
<td>41–0/7</td>
<td>39–4/7</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>Eclamptic fit</td>
<td>37–3/7</td>
<td>PP 3d</td>
<td>36–3/7</td>
<td>PP 0.1h</td>
<td>PP0.5h</td>
<td>40–2/7</td>
<td>PP2.5h</td>
<td>PP3h</td>
<td>PP0.5h</td>
<td>40–5/7</td>
<td>40–4/7</td>
</tr>
<tr>
<td>Mode of delivery</td>
<td>CS</td>
<td>TV</td>
<td>CS</td>
<td>CS</td>
<td>TV</td>
<td>CS</td>
<td>TV</td>
<td>TV</td>
<td>TV</td>
<td>TV</td>
<td>TV</td>
</tr>
<tr>
<td>PIATD</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>EOWG</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Laboratory data†</td>
<td>AST &gt;40 IU/L</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LDH &gt;400 IU/L</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Platelet &lt; 120×10⁹/L</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Infant</td>
<td>Sex</td>
<td>male</td>
<td>male</td>
<td>female</td>
<td>female</td>
<td>male</td>
<td>male</td>
<td>male</td>
<td>female</td>
<td>male</td>
<td>female</td>
</tr>
<tr>
<td>Weight (g)</td>
<td>2,334</td>
<td>4,034</td>
<td>2,060</td>
<td>3,782</td>
<td>2,062</td>
<td>2,772</td>
<td>3,590</td>
<td>2,812</td>
<td>3,310</td>
<td>2,976</td>
<td>3,368</td>
</tr>
<tr>
<td>MRI</td>
<td>RPLS</td>
<td>RPLS</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NA</td>
<td>NE</td>
<td>NE</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Sequela</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>HP</td>
</tr>
</tbody>
</table>

*Time when hypertension and/or proteinuria was seen antenatally for the first time.

Hypertension was defined as systolic blood pressure of ≥140 mmHg and/or diastolic blood pressure of ≥90 mmHg. Proteinuria was defined as protein loss in the urine ≥0.3g/day.

PP, postpartum; PIATD, pregnancy-induced antithrombin deficiency; EOWG, extraordinary weight gain; CS, cesarean delivery; TV, transvaginal delivery; HP, hypopituitarism

†Presence (+) or absence (-) of transient elevation of serum AST and LDH, and transient thrombocytopenia during 3 days prior to and 4 days after eclamptic fit.

MRI, magnetic resonance imaging; RPLS, reversible posterior leukoencephalopathy syndrome; NE, not examined; NA, no abnormality.

Brain hemorrhage was ruled out in all 11 women with brain computed tomography.
Table 2. Changes in body weight from the day of delivery according to weight gain during the last two antenatal weeks in 272 control women

<table>
<thead>
<tr>
<th>Antenatal weight gain (kg)</th>
<th>Postnatal weight loss (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>one week</td>
</tr>
<tr>
<td>Groups according to antenatal weight gain</td>
<td></td>
</tr>
<tr>
<td>&lt; 2.5th percentile</td>
<td>-2.6±1.3</td>
</tr>
<tr>
<td>( &lt; -1.66kg, n=6)</td>
<td></td>
</tr>
<tr>
<td>2.5th to 97.5th percentile</td>
<td>0.9±0.9</td>
</tr>
<tr>
<td>( -1.66kg to 4.01kg, n=260)</td>
<td></td>
</tr>
<tr>
<td>&gt;97.5th percentile</td>
<td>6.2±2.2</td>
</tr>
<tr>
<td>( &gt;4.01kg, n=6)</td>
<td></td>
</tr>
</tbody>
</table>

Data are expressed as mean±SD.

§ p<0.005 and 0.05 vs women group with an antenatal weight gain of < 2.5th percentile and of 2.5th to 97.5th percentile, respectively.
<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Frequency of eclampsia</th>
<th>RR (95% CI)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIATD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1.7% (6/356)</td>
<td>57.9 (17.7–188.7)</td>
</tr>
<tr>
<td>No</td>
<td>0.029% (5/17,166)</td>
<td>1.0</td>
</tr>
<tr>
<td>EOWG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>0.46% (2/439)</td>
<td>8.65 (1.87–39.91)</td>
</tr>
<tr>
<td>No</td>
<td>0.053% (9/17,083)</td>
<td>1.0</td>
</tr>
</tbody>
</table>

RR (95% CI)*, relative risk (95% confidence interval).

These risks were calculated based on the assumption that the prevalence of PIATD would be 2.0% (350 women) and 437 women (2.5%) exhibited a weight gain > 4.01 kg during the last two antenatal weeks among 17,511 women who did not develop eclampsia.

Table 3. Risk of eclampsia among women with pregnancy-induced antithrombin deficiency (PIATD) or extraordinary weight gain (EOWG).